Particle.news
Clinical Trials Autism Studies Epidemiology HIV Vaccines Vaccine Efficacy Thimerosal Studies Immunology COVID-19 Vaccines Ethics in Research Adverse Event Reporting Autism and Vaccines Therapeutics Safety Studies Influenza Vaccines Autism Research mRNA Vaccines mRNA Research Efficacy Studies Vaccine Efficacy Studies Vaccine Effectiveness Data Transparency Public Health Research Thimerosal Controversy Peer-Reviewed Studies Vaccine Safety Studies Aluminum in Vaccines
The move shrinks its staff to under 5,000 by year-end to cut $1.5 billion in annual expenses by 2027.
